Novo Nordisk diabetes / weightloss drug semaglutide locked in a legal tangle with DRL
A legal tangle hovers over Novo Nordisk’s diabetes and weightloss drug semaglutide, just weeks ahead of the possible launch of its injectible version Wegovy in India. Semaglutide is the active ingredient in the drug that’s globally popular as Ozempic / Wegovy, and the Danish company making the drug is presently locked in a patent infringement
